Alector Inc (ALEC) - Total Liabilities
Based on the latest financial reports, Alector Inc (ALEC) has total liabilities worth $262.59 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Alector Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Alector Inc's total liabilities have evolved over time, based on quarterly financial data. See ALEC working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Alector Inc Competitors by Total Liabilities
The table below lists competitors of Alector Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LIWANLI Innovation Co Ltd
TW:3054
|
Taiwan | NT$32.86 Million |
|
New World Resources Ltd
AU:NWC
|
Australia | AU$1.75 Million |
|
Cartesian Therapeutics Inc.
NASDAQ:RNAC
|
USA | $436.51 Million |
|
Garuda Construction & Engineering
NSE:GARUDA
|
India | Rs1.90 Billion |
|
Hyosung Chemical Corp
KO:298000
|
Korea | ₩1.96 Trillion |
|
Group Eleven Resources Corp
V:ZNG
|
Canada | CA$940.88K |
|
Toro Ltd
NASDAQ:TORO
|
USA | $4.05 Million |
|
Kangstem Biotech Co. Ltd
KQ:217730
|
Korea | ₩12.20 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Alector Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALEC company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 8.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.90 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alector Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alector Inc (2016–2025)
The table below shows the annual total liabilities of Alector Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $262.59 Million | -23.11% |
| 2024-12-31 | $341.50 Million | -29.97% |
| 2023-12-31 | $487.67 Million | -14.92% |
| 2022-12-31 | $573.21 Million | +11.53% |
| 2021-12-31 | $513.93 Million | +132.84% |
| 2020-12-31 | $220.72 Million | -2.84% |
| 2019-12-31 | $227.17 Million | -44.01% |
| 2018-12-31 | $405.76 Million | +40.84% |
| 2017-12-31 | $288.09 Million | +264.59% |
| 2016-12-31 | $79.02 Million | -- |
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheim… Read more